Last reviewed 2026-04-20 · How we verify

Orap (PIMOZIDE)

Pimozide (Orap), marketed by Teva, is a serotonin 5-hydroxytryptamine receptor 7 antagonist primarily indicated for Tourette's Disorder. A key strength of Pimozide is its strong patent protection until 2028, providing a barrier to generic competition. The primary risk is the presence of multiple off-patent competitors with the same target, such as amitriptyline and amoxapine, which may limit market share and revenue potential.

At a glance

Approved indications

• Tourette's Disorder

Common side effects

• Somnolence
• Asthenia
• Headache
• Adverse Behavior Effect
• Nervous
• Rash
• Visual Disturbance
• Hyperkinesia
• Tremor, Limbs
• Dysphagia
• Increased Salivation
• Myalgia

Drug interactions

• High Risk QT Prolonging Agents
• cabergoline
• dalfopristin
• delavirdine
• entacapone
• haloperidol
• indinavir
• itraconazole
• ketoconazole
• levodopa
• nelfinavir
• pergolide

Key clinical trials

• Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis (PHASE2)
• Electrophysiological Effects of Potential QT Prolonging Drugs (PHASE1)
• Treatment for Post Acute COVID-19 Syndrome (NA)
• Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
• A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) (PHASE2)
• Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
• Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (PHASE4)
• Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.